Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. (Q53175859)
Jump to navigation
Jump to search
scientific article published on 2 April 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. |
scientific article published on 2 April 2012 |
Statements
Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. (English)
1 reference
John Mascarenhas
1 reference
Ronald Hoffman
1 reference
2 April 2012
1 reference
18
1 reference
3008-3014
1 reference
11
1 reference
Identifiers
1 reference